Hsp90 Activity Modulation by Plant Secondary Metabolites

Planta Medica

Volumn 81, Issue 14, 2015, Pages 1223-1239

  Piaz, Fabrizio Dal ^a   Terracciano, Stefania ^a   De Tommasi, Nunziatina ^a   Braca, Alessandra ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

client proteins; Hsp90; Hsp90 inhibitors; plant molecules

Indexed keywords

ALKALOID; ANTHRAQUINONE DERIVATIVE; BIFLAVONOID; CATECHIN; CELASTROL; CHALCONE DERIVATIVE; COUMARIN DERIVATIVE; DEGUELIN; DITERPENE; EPIGALLOCATECHIN GALLATE; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; GEDUNIN; HEAT SHOCK PROTEIN 90; HORMONE RECEPTOR; IRIDOID; ISOFLAVONE DERIVATIVE; LENTIGINOSINE; LIMONOID; MISCELLANEOUS DRUGS AND AGENTS; NUCLEAR HORMONE RECEPTOR; ONCOPROTEIN; PHOSPHOTRANSFERASE; PLANT MEDICINAL PRODUCT; SESQUITERPENE; TANNIN DERIVATIVE; TERPENE; TRANSCRIPTION FACTOR; TRITERPENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; FLAVONOID;

ARTICLE; BIOCHEMICAL ANALYSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; COLD STRESS; DRUG DEVELOPMENT; DRUG RESEARCH; ENVIRONMENTAL STRESS; HEAT STRESS; IC50; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; NONHUMAN; OXYGEN DEPRIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM; PLANT; SECONDARY METABOLISM;

ALKALOIDS; ANIMALS; ANTHRAQUINONES; COUMARINS; FLAVONOIDS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PHYTOCHEMICALS; PLANTS; SECONDARY METABOLISM; TANNINS; TERPENES;

EID: 84942068020     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0035-1546251     Document Type: Article

References (158)

1. Zhang H., Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med: 2004; 82 488 499
2. Whitesell L., Lindquist S. L. Hsp90 and the chaperoning of cancer. Nat Rev Cancer: 2005; 5 761 772
3. Pearl L. H., Prodromou C. Structure and in vivo function of Hsp90. Curr Opin Struct Biol: 2000; 10 46 51
4. Patki J. M., Pawar S. S. Hsp90: chaperone-me-not. Pathol Oncol Res: 2013; 19 631 640
5. Scheibel T., Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem Pharmacol: 1998; 56 675 682
6. Solit D. B., Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem: 2006; 6 1205 1214
7. Holzbeierlein J. M., Windsperger A., Vielhauer G. Hsp90: a drug target? Curr Oncol Rep: 2010; 12 95 101
8. Jego G., Hazoume A., Seigneuric R., Garrido C. Targeting heat shock proteins in cancer. Cancer Lett: 2013; 332 275 285
9. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res: 2012; 18 64 76
10. Bhat R., Tummalapalli S. R., Rotella D. P. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. J Med Chem: 2014; 57 8718 8728
11. Carlson E. E. Natural products as chemical probes. ACS Chem Biol: 2010; 5 639 653
12. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol: 2006; 172 259 277
13. Jhaveri K., Ochiana S. O., Dunphy M. P., Gerecitano J. F., Corben A. D., Peter R. I., Janjigian Y. Y., Gomes-DaGama E. M., Koren J. 3rd, Modi S., Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs: 2014; 23 611 628
14. Patel D., Shukla S., Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol: 2007; 30 233 245
15. Shukla S., Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Res: 2010; 27 962 978
16. Simons A. L., Renouf M., Hendrich S., Murphy P. A. Human gut microbial degradation of flavonoids: structure-function relationships. J Agric Food Chem: 2005; 53 4258 4263
17. Tang D., Yu Y., Zheng X., Wu J., Li Y., Wu X., Du Q., Yin X. Comparative investigation of in vitro biotransformation of 14 components in Ginkgo biloba extract in normal, diabetes and diabetic nephropathy rat intestinal bacteria matrix. J Pharm Biomed Anal: 2014; 100 1 10
18. Osada M., Imaoka S., Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1 α protein. FEBS Lett: 2004; 575 59 63
19. Zhao M., Ma J., Zhu H. Y., Zhang X. H., Du Z. Y., Xu Y. J., Yu X. D. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer: 2011; 10 104
20. Miski M., Ulubelen A., Johansson C., Mabry T. J. Antibacterial activity studies of flavonoids from Salvia palaestina. J Nat Prod: 1983; 46 874 875
21. Wolfman C., Viola H., Paladini A., Dajas F., Medina J. H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav: 1994; 47 1 4
22. Brown E., Hurd N. S., McCall S., Ceremuga T. E. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J: 2007; 75 333 337
23. Lapidot T., Walker M. D., Kanner J. Antioxidant and prooxidant effects of phenolics on pancreatic β -cells in vitro. J Agric Food Chem: 2002; 50 7220 7250
24. Cho H., Yun C. W., Park W. K., Kong J. Y., Kim K. S., Park Y., Lee S., Kim B. K. Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives. Pharmacol Res: 2004; 49 37 43
25. Fu B., Xue J., Li Z., Shi X., Jiang B. H., Fang J. Chrysin inhibits expression of hypoxia-inducible factor-1 α through reducing hypoxia-inducible factor-1 α stability and inhibiting its protein synthesis. Mol Cancer Ther: 2007; 6 220 226
26. Seo H. J., Surh Y. J. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human promyelocytic leukemia cells. Mutat Res: 2001; 496 191 198
27. Kim J. M., Lee D. H., Kim J. S., Lee J. Y., Park H. G., Kim Y. J., Oh Y. K., Jung H. C., Kim S. I. 5,7-dihydroxy-3,4,6-trimethoxyflavone inhibits the inflammatory effects induced by Bacteroides fragilis enterotoxin via dissociating the complex of heat shock protein 90 and IkB α and IkB kinase- γ in intestinal epithelial cell culture. Clin Exp Immunol: 2009; 155 541 551
28. Gábor M. Anti-inflammatory and anti-allergic properties of flavonoids. Prog Clin Biol Res: 1986; 213 471 480
29. Seelinger G., Merfort I., Schempp C. M. Antioxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med: 2008; 74 1667 1677
30. Seelinger G., Merfort I., Wölfle U., Schempp C. M. Anti-carcinogenic effects of the flavonoid luteolin. Molecules: 2008; 13 2628 2651
31. Serra A., Macià A., Romero M. P., Reguant J., Ortega N., Motilva M. J. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem: 2012; 130 383 393
32. Chen C Y. C., Chen G. W., Chen W. YC. Molecular simulation of HER2/neu degradation by inhibiting Hsp90. J Chin Chem Soc: 2008; 55 297 302
33. Fu J., Chen D., Zhao B., Zhao Z., Zhou J., Xu Y., Xin Y., Liu C., Luo L., Yin Z. Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3. PLoS One: 2012; 7 e49194
34. Hong Z., Cao X., Li N., Zhang Y., Lan L., Zhou Y., Pan X., Shen L., Yin Z., Luo L. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol: 2014; 171 2842 2853
35. Chen D., Bi A., Dong X., Jiang Y., Rui B., Liu J., Yin Z., Luo L. Luteolin exhibits anti-inflammatory effects by blocking the activity of heat shock protein 90 in macrophages. Biochem Biophys Res Commun: 2014; 443 326 332
36. Alfonso D., Kapetanidis I. Flavonoids from Iochroma gesnerioides. Pharm Acta Helv: 1994; 68 211 214
37. Tamura M., Hirayama K., Itoh K. Role of intestinal flora on the metabolism, absorption, and biological activity of dietary flavonoids. Bioscience Microflora: 2003; 22 125 131
38. Middleton E. jr., Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol: 1992; 43 1167 1179
39. Wang H. K. The therapeutic potential of flavonoids. Expert Opin Investig Drugs: 2000; 9 2103 2119
40. Dechsupa S., Kothan S., Vergote J., Leger G., Martineau A., Beranger S., Kosanlavit R., Moretti J. L., Mankhetkorn S. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-MB-435 cells xenograft in vivo. Cancer Biol Ther: 2007; 6 56 61
41. Davies S. P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J: 2000; 351 95 105
42. Harwood M., Danielewska-Nikiel B., Borzelleca J. F., Flamm G. W., Williams G. M., Lines T. C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol: 2007; 45 2179 2205
43. Nagai N., Nakai A., Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun: 1995; 208 1099 1105
44. Aalinkeel R., Bindukumar B., Reynolds J. L., Sykes D. E., Mahajan S. D., Chadha K. C., Schwartz S. A. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate: 2008; 68 1773 1789
45. Wang R. E., Hunt C. R., Chen J., Taylor J. S. Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. Bioorg Med Chem: 2011; 19 4710 4720
46. Jeong J. H., An J. Y., Kwon Y. T., Li L. Y., Lee Y. J. Quercetin-induced ubiquitination and down regulation of Her-2/neu. J Cell Biochem: 2008; 105 585 595
47. East A. J., Ollis W. D., Wheeler R. E. Natural occurrence of 3-aryl-4-hydroxycoumarins. Part I. Phytochemical examination of Derris robusta (roxb) benth. J Chem Soc C: 1969; 3 365 373
48. Hadden M. K., Galam L., Gestwicki J. E., Matts R. L., Blagg B. SJ. Derrubone, an inhibitor of the Hsp90 protein folding machinery. J Nat Prod: 2007; 70 2014 2018
49. Li Y., Zhang T., Schwartz S. J., Sun D. New developments in Hsp90 inhibitors as anticancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat: 2009; 12 17 27
50. El Hamidieh A., Grammatikakis N., Patsavoudi E. Cell surface Cdc37 participates in extracellular Hsp90 mediated cancer cell invasion. PLoS One: 2012; 7 1 9
51. Özgür A., Tutar Y. Heat shock protein 90 inhibitors in oncology. Curr Proteomics: 2014; 11 2 16
52. Hastings J. M., Hadden M. K., Blagg B. S. Synthesis and evaluation of derrubone and select analogues. J Org Chem: 2008; 73 369 373
53. Mays J. R., Hill S. A., Moyers J. T., Blagg B. S. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorg Med Chem: 2010; 18 249 266
54. Khalid S., Paul S. Identifying a C-terminal ATP binding sites-based novel Hsp90-inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease. Med Hypotheses: 2014; 83 39 46
55. Roux D. G., Paulus E. Condensed tannins. 10. Isolation of (-)-butin and butein from wattle heartwoods. Biochem J: 1961; 80 62 63
56. Wang Z., Lee Y., Eun J. S., Bae E. J. Inhibition of adipocyte inflammation and macrophage chemotaxis by butein. Eur J Pharmacol: 2014; 738 40 48
57. Lee S. H., Seo G. S., Sohn D. H. Inhibition of lipopolysaccharide-induced expression of inducible nitricoxide synthase by butein in RAW264.7 cells. Biochem Biophys Res Commun: 2004; 323 125 132
58. Lee S. H., Nan J. X., Zhao Y. Z., Woo S. W., Park E. J., Kang T. H., Seo G. S., Kim Y. C., Sohn D. H. Thechalcone butein from Rhus verniciflua shows anti-fibrogenic activity. Planta Med: 2003; 69 990 994
59. Pandey M. K., Sandur S. K., Sung B., Sethi G., Kunnumakkara A. B., Aggarwal B. B. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem: 2007; 282 17340 17350
60. Chua A. W., Hay H. S., Rajendran P., Shanmugam M. K., Li F., Bist P., Koay E. S., Lim L. H., Kumar A. P., Sethi G. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF- κ B activation in breast and pancreatic tumor cells. Biochem Pharmacol: 2010; 80 1553 1562
61. Lau G. T., Huang H., Lin S. M., Leung L. K. Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells. Eur J Pharmacol: 2010; 648 24 30
62. Rajendran P., Ong T. H., Chen L., Li F., Shanmugam M. K., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A. P., Hui K. M., Sethi G. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res: 2011; 17 1425 1439
63. Seo Y. H. Butein disrupts Hsp90′s molecular chaperoning function and exhibits anti-proliferative effects against drug-resistant cancer cells. Bull Korean Chem Soc: 2013; 34 3345 3349
64. Seo Y. H., Jeong J. H. Synthesis of butein analogues and their anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) through Hsp90 inhibition. Bull Korean Chem Soc: 2014; 35 1294 1298
65. Kuo Y. F., Su Y. Z., Tseng Y. H., Wang S. Y., Wang H. M., Chueh P. J. Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells. Free Radic Biol Med: 2010; 49 214 226
66. Henderson B. E., Kolonel L. N., Dworsky R., Kerford D., Mori E., Singh K., Thevenot H. Cancer incidence in the islands of the Pacific. Natl Cancer Inst Monogr: 1985; 69 73 81
67. Steiner G. G. The correlation between cancer incidence and kava consumption. Hawaii Med J: 2000; 59 420 422
68. Warmka J. K., Solberg E. L., Zeliadt N. A., Srinivasan B., Charlson A. T., Xing C., Wattenberg E. V. Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochem Biophys Res Commun: 2012; 424 488 492
69. Sakai T., Eskander R. N., Guo Y., Kim K. J., Mefford J., Hopkins J., Bhatia N. N., Zi X., Hoang B. H. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res: 2012; 30 1045 1050
70. Lin E., Lin W. H., Wang S. Y., Chen C. S., Liao J. W., Chang H. W., Chen S. C., Lin K. Y., Wang L., Yang H. L., Hseu Y. C. Flavokawain B inhibits growth of human squamous carcinoma cells: involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem: 2012; 23 368 378
71. Li X., Liu Z., Xu X., Blair C. A., Sun Z., Xie J., Lilly M. B., Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One: 2012; 7 e31213
72. Ji T., Lin C., Krill L. S., Eskander R., Guo Y., Zi X., Hoang B. H. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer: 2013; 12 55
73. Seo Y. H., Oh Y. J. Synthesis of flavokawain B and its anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC). Bull Korean Chem Soc: 2013; 34 3782 3786
74. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi: 2000; 120 849 862
75. Hatano T., Kagawa H., Yasuhara T., Okuda T. Two new flavonoids and other constituents in licorice root: their relative astringency and radical scavenging effects. Chem Pharm Bull (Tokyo): 1988; 36 2090 2097
76. Fu Y., Hsieh T. C., Guo J., Kunicki J., Lee M. Y., Darzynkiewicz Z., Wu J. M. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun: 2004; 322 263 270
77. Xiao X. Y., Hao M., Yang X. Y., Ba Q., Li M., Ni S J., Wang L. S., Du X. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett: 2011; 1 69 75
78. Chu X., Ci X., Wei M., Yang X., Cao Q., Guan M., Li H., Deng Y., Feng H., Deng X. Licochalcone A inhibits lipopolysaccharide-induced inflammatory response in vitro and in vivo. J Agric Food Chem: 2012; 60 3947 3954
79. Landis-Piwowar K. R., Huo C., Chen D., Milacic V., Shi G., Chan T. H., Dou Q. P. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res: 2007; 67 4303 4310
80. Palermo C. M., Westlake C. A., Gasiewicz T. A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 KDa heat shock protein. Biochemistry: 2005; 44 5041 5052
81. Yin Z., Henry E. C., Gasiewicz T. A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry: 2009; 48 336 345
82. Li Y., Zhang T., Jiang Y., Lee H. F., Schwartz S. J., Sun D. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm: 2009; 6 1152 1159
83. Tran P. L., Kim S. A., Choi H. S., Yoon J. H., Ahn S. G. Epigallocatechin-3-gallate suppresses the expression of Hsp70 and Hsp90 and exhibits antitumor activity in vitro and in vivo. BMC Cancer: 2010; 10 276
84. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H. Targeting multiple signalling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res: 2006; 66 2500 2505
85. Li M., He Z., Ermakova S., Zheng D., Tang F., Cho Y. Y., Zhu F., Ma W. Y., Sham Y., Rogozin E. A., Bode A. M., Cao Y., Dong Z. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev: 2007; 16 598 605
86. Ramirez-Sanchez I., Aguilar U., Ceballos G., Villarreal F. (-)-Epicatechin-induced calcium independent eNOS activation: roles of Hsp90 and AKT. Mol Cell Biochem: 2012; 370 141 150
87. Halder B., Das Gupta S., Gomes A. Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signalling. Possible involvement of Hsp90, Wnt/ β -catenin signalling and FOXO1. FEBS J: 2012; 279 2876 2891
88. Malafronte N., Vassallo A., Dal Piaz F., Bader A., Braca A., De Tommasi N. Biflavonoids from Daphne linearifolia Hart. Phytochemistry Lett: 2012; 5 621 625
89. Marcu M. G., Chadli A., Bouhouche I., Catelli M., Neckers L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem: 2000; 275 37181 37186
90. Kimura S., Ito C., Jyoko N., Segawa H., Kuroda J., Okada M., Adachi S., Nakahata T., Yuasa T., Filho V. C., Furukawa H., Maekawa T. Inhibition of leukemic cell growth by a novel anticancer drug (GUT-70) from Calophyllum brasiliense that acts by induction of apoptosis. Int J Cancer: 2005; 113 158 165
91. Jin L., Tabe Y., Kimura S., Zhou Y., Kuroda J., Asou H., Inaba T., Konopleva M., Andreeff M., Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. British J Cancer: 2011; 104 91 100
92. Lu Y. Anthraquinones. In Xu R, Ye Y, Zhao W, editors. Introduction to natural products chemistry. London CRC Press: 2012; 189 203
93. Huang P. H., Huang C. Y., Chen M. C., Lee Y. T., Yue C. H., Wang H. Y., Lin H. Emodin and aloe-emodin suppress breast cancer cell proliferation through ER inhibition. Evid Based Complement Alternat Med: 2013; 2013 376123
94. Yan Y. Y., Zheng L. S., Zhang X., Chen L. K., Singh S., Wang F., Zhang J. Y., Liang Y. J., Dai C. L., Gu L. Q., Zheng M. S., Talele T. T., Chen Z. S., Fu L. W. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol Pharmaceut: 2011; 8 1687 1697
95. Fernand V. E., Losso J. N., Truax R. E., Villar E. E., Bwambok D. K., Fakayode S. O., Lowry M., Warner I. M. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro. Chem Biol Interact: 2011; 192 220 232
96. Vassallo A., Vaccaro M. C., De Tommasi N., Dal Piaz F., Leone A. Identification of the plant compound geraniin as a novel Hsp90 inhibitor. PLoS One: 2013; 8 e74266
97. Li J., Wang S., Yin J., Pan L. Geraniin induces apoptotic cell death in human lung adenocarcinoma A549 cells in vitro and in vivo. Can J Physiol Pharm: 2013; 91 1016 1024
98. Zhang X-C, Chen P., He B., Wang N., Shen Z-Q. Influence of geraniin on carbonic anhydrase type II (CA II) protein in osteoclasts. Shizhen Guoyi Guoyao: 2013; 24 804 807
99. Zhang X-C, Guo Y., He B., Wang N., Chen P., Shen Z-Q. Effect of geraniin on expression of carbonic anhydrase II mRNA in cultured osteoclasts. Zhongyao Yaoli Yu Linchuang: 2013; 29 32 34
100. Bing S. J., Ha D., Kim M. J., Park E., Ahn G., Kim D. S., Ko R. K., Park J. W., Lee N. H., Jee Y. Geraniin down regulates gamma radiation-induced apoptosis by suppressing DNA damage. Food Chem Toxicol: 2013; 57 147 153
101. Yang Y., Zhang L., Fan X., Qin C., Liu J. Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorg Med Chem Lett: 2012; 22 2209 2211
102. Serrano J., Puupponen-Pimia R., Dauer A., Aura A. M., Saura-Calixto F. Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol Nutr Food Res: 2009; 53 S310 S329
103. Bhattacharjee B., Vijayasarathy S., Karunakar P., Chatterjee J. Comparative reverse screening approach to identify potential anti-neoplastic targets of saffron functional components and binding mode. Asian Pac J Cancer Prev: 2012; 13 5605 5611
104. Dal Piaz F., Vassallo A., Temraz A., Cotugno R., Belisario M. A., Bifulco G., Chini M. G., Pisano C., De Tommasi N., Braca A. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. J Med Chem: 2013; 56 1583 1595
105. Beauchamp J. K., Keast R. S., Morel D., Lin J., Pika J., Han Q., Lee C. H., Smith A. B., Breslin P. A. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature: 2005; 437 45 46
106. Margarucci L., Monti M. C., Cassiano C., Mozzicafreddo M., Angeletti M., Riccio R., Tosco A., Casapullo A. Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor. Chem Commun: 2013; 49 5844 5846
107. Zhao Y. S., Zhu T. Z., Chen Y. W., Yao Y. Q., Wu C. M., Wei Z. Q., Wang W., Xu Y. H. β -elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells. J Neurooncol: 2012; 107 307 314
108. Ohnishi K., Ohkura S., Nakahata E., Ishisaka A., Kawai Y., Terao J., Mori T., Ishii T., Nakayama T., Kioka N., Matsumoto S., Ikeda Y., Akiyama M., Irie K., Murakami A. Non-specific protein modifications by a phytochemical induce heat shock response for self-defense. PLoS One: 2013; 83 e58641
109. Chao W. W., Lin B. F. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin Med: 2010; 5 17
110. Bao Z., Guan S., Cheng C., Wu S., Wong S. H., Kemeny D. M., Leung B. P., Wong W. S. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor- κ B pathway. Am J Respir Crit Care Med: 2009; 179 657 665
111. Lim J. C., Chan T. K., Ng D. S., Sagineedu S. R., Stanslas J., Wong W. S. Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. Clin Exp Pharmacol Physiol: 2012; 39 300 310
112. Abu-Ghefreh A. A., Canatan H., Ezeamuzie C. I. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol: 2009; 9 313 318
113. Liang F. P., Lin C. H., Kuo C. D., Chao H. P., Fu S. L. Suppression of v-Src transformation by andrographolide via degradation of the v-Src protein and attenuation of the Erk signaling pathway. J Biol Chem: 2008; 283 5023 5033
114. Liu S. H., Lin C. H., Liang F. P., Chen P. F., Kuo C. D., Alam M. M., Maiti B., Hung S. K., Chi C. W., Sun C. M., Fu S. L. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol: 2014; 87 229 242
115. Druckova A., Mernaugh R. L., Ham A. J., Marnett L. J. Identification of the protein targets of the reactive metabolite of Teucrin A in vivo in the rat. Chem Res Toxicol: 2007; 20 1393 1408
116. Mohebati A., Guttenplan J. B., Kochhar A., Zhao Z. L., Kosinska W., Subbaramaiah K., Dannenberg A. J. Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev Res: 2012; 5 593 602
117. Hughes D., Guttenplan J. B., Marcus C. B., Subbaramaiah K., Dannenberg A. J. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res: 2008; 1 485 493
118. Zhou Z. W., Xie X. L., Zhou S. F., Li C. G. Mechanism of reversal of high glucose-induced endothelial nitric oxide synthase uncoupling by tanshinone IIA in human endothelial cell line EA.hy926. Eur J Pharmacol: 2012; 697 97 105
119. Lamb J., Crawford E. D., Peck D., Modell J. W., Blat I. C., Wrobel M. J., Lerner J., Brunet J-P, Subramanian A., Ross K. N., Reich M., Hieronymus H., Wei G., Armstrong S. A., Haggarty S. J., Clemons P. A., Wei R., Carr S. A. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science: 2006; 313 1929 1935
120. Hieronymus H., Lamb J., Ross K. N., Peng X. P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S. M., Maloney K. N., Clardy J., Hahn W. C., Chiosis G., Golub T. R. Gene expression signature-based chemical genomic prediction identifies a novel class of Hsp90 pathway modulators. Cancer Cell: 2006; 10 321 330
121. Brandt G. EL, Schmidt M. D., Prisinzano T. E., Blagg B. SJ. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem: 2008; 51 6495 6502
122. Dal Piaz F., Malafronte N., Romano A., Gallotta D., Belisario M. A., Bifulco G., Gualtieri M. J., Sanogo R., De Tommasi N., Pisano C. Structural characterization of tetranortriterpenes from Pseudrocedrela kotschyi and Trichilia emetica and study of their activity towards the chaperone Hsp90. Phytochemistry: 2012; 75 78 89
123. Gualtieri M. J., Malafronte N., Vassallo A., Braca A., Cotugno R., Vasaturo M., De Tommasi N., Dal Piaz F. Bioactive limonoids from the leaves of Azaridachta indica (Neem). J Nat Prod: 2014; 77 596 602
124. Morota T., Yang C. X., Sasaki H., Qin W. Z., Sugama K., Miao K. L., Yoshino T., Xu L. H., Maruno M., Yang B. H. Triterpenes from Tripterygium wilfordii. Phytochemistry: 1995; 39 1153 1157
125. Salminen A., Lethonen M., Paimela T., Kaarniranta K. Celastrol: Molecular targets of Thunder God Vine. Biochem Biophys Res Commun: 2010; 394 439 442
126. Davenport A., Frezza M., Shen M., Ge Y., Huo C., Chan T. H., Dou Q. P. Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int J Mol Med: 2010; 25 465 470
127. Deng Y. N., Shi J., Liu J., Qu Q. M. Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int: 2013; 63 1 9
128. Petronelli A., Pannitteri G., Testa U. Triterpenoids as new anticancer drugs. Anticancer Drugs: 2009; 20 880 892
129. Yang H., Chen D., Cui Q. C., Yuan X., Dou Q. P. Celastrol, a triterpene extracted from the Chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res: 2006; 66 4758 4765
130. Cheng G., Zhang X., Zhao M., Yan W., Chen X., Wang D., Xu Y., Du Z., Yu X. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer: 2011; 11 170
131. Peng B., Xu L., Cao F., Wei T., Yan C., Uzan G., Zhang D. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer: 2010; 9 79
132. Kim K., Lee H., Han S., Lee Y., Choe J., Kim Y., Hahn J., Ro J., Jeoung D., Kim Y. Celastrol binds to ERK and inhibits Fc ε RI signaling to exert an anti-allergic effect. Eur J Pharmacol: 2009; 612 131 142
133. Sha M., Ye J., Zhang L. X., Luan Z. Y., Chen Y. B., Huang J. X. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF- κ B signaling pathway. Pharmacology: 2014; 93 39 46
134. Kannaiyan R., Manu K. A., Chen L., Li F., Rajendran P., Subramaniam A., Lam P., Kumar A. P., Sethi G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N -terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis: 2011; 16 1028 1041
135. Fan X. X., Li N., Wu J. L., Zhou Y. L., He J. X., Liu L., Leung E. LH. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. Molecules: 2014; 19 3508 3522
136. Feng L., Zhang D., Fan C., Ma C., Yang W., Meng Y., Wu W., Guan S., Jiang B., Yang M. ER stress-mediated apoptosis induced by celastrol in cancer cells and important role of glycogen synthase kinase-3 β in the signal network. Cell Death Dis: 2013; 4 e715
137. Lu Z., Jin Y., Qiu L., Lai Y., Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett: 2010; 290 182 191
138. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C. G., Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther: 2008; 7 162 170
139. Sreeramulu S., Gande S. L., Göbel M., Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinone chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed: 2009; 48 5853 5855
140. Zhang T., Li Y., Yu Y., Zou P., Jiang Y., Sun D. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J Biol Chem: 2009; 284 35381 35389
141. Chadli A., Felts S. J., Wang Q., Sullivan W. P., Botuyan M. V., Fauq A., Ramirez-Alvarado M., Mer G. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. J Biol Chem: 2010; 285 4224 4231
142. Zhang D., Xu L., Cao F., Wei T., Yang C., Uzan G., Peng B. Celastrol regulates multiple nuclear transcription factors belonging to Hsp90′s clients in a dose- and cell type-dependent way. Cell Stress Chaperon: 2010; 15 939 946
143. Zanphorlin L. M., Alves F. R., Ramos C. H. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90 KDa heat shock protein Hsp90 α, a chaperone implicated in the stabilization of the tumor phenotype. Biochim Biophys Acta: 2014; 1840 3145 3152
144. Pyo J. S., Roh S. H., Kim D. K., Lee J. G., Lee Y. Y., Hong S. S., Kwon S. W., Park J. H. Anticancer effect of betulin on a human lung cancer cell line: a pharmacoproteomic approach using 2DSDS PAGE coupled with nano-HPLC tandem mass spectrometry. Planta Med: 2009; 75 127 131
145. Ding L., Xu F. C., Wang H., Ou Q. M. Studies on chemical constituents from Patrinia heterophylla Bunge and their cytotoxicity in vitro. J Northwest Normal University (Natural Science): 2007; 43 62 65
146. Wei D. F., Wei Y. X., Cheng W. D., Yan M. F., Su G., Hu Y., Ma Y. Q., Han C., Lu Y., Cao H. M., Bao Y. C. Proteomic analysis of the effect of triterpenes from Patrinia heterophylla on leukemia K562 cells. J Ethnopharmacol: 2012; 144 576 583
147. Haginaka J., Kitabatake T., Hirose I., Matsunaga H., Moaddel R. Interaction of cepharanthine with immobilized heat shock protein 90 α (Hsp90 α) and screening of Hsp90 α inhibitors. Anal Biochem: 2013; 434 202 206
148. Rogosnitzky M., Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep: 2011; 63 337 347
149. Tang J., Feng Y., Tsao S., Wang N., Curtain R., Wang Y. Berberine and Coptidis rhizome as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol: 2009; 126 5 17
150. Rahmatullah M., Jahan R., Bashar A. BMA, Al-Nahain A., Majumder S., Islam T., Das P. R. A review on berbamine - a potential anticancer drug. J Pharm Pharm Sci: 2014; 3 95 110
151. Diogo C. V., Machado N. G., Barbosa I. A., Serafim T. L., Burgeiro A., Oliveira P. J. Berberine as a promising safe anticancer agent - is there a role for mitochondria? Curr Drug Targets: 2011; 12 850 859
152. Jabbarzadeh K. P., Rahmat A., Ismail P., Ling K. H. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol: 2014; 740 584 595
153. Sun J. R., Zhang X. H., He Z. W., Gu Y., Yu Y. Z., Fang Y. M., Lu Q. H., Dong Q. H., Xu R. Z. The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine. Zhonghua Yi Xue Za Zhi: 2006; 86 2246 2251
154. Dal Piaz F., Vassallo A., Chini M. G., Cordero F. M., Cardona F., Pisano C., Bifulco G., De Tommasi N., Brandi A. Natural iminosugar (+)-lentiginosine inhibits ATPase and chaperone activity of hsp90. PloS One: 2012; 7 e43316
155. Pastuszak I., Molyneux R. J., James L. F., Elbein A. D. Lentiginosine, a dihydroxyindolizidine alkaloid that inhibits amyloglucosidase. Biochemistry: 1990; 29 1886 1891
156. Ren Y., Yuan C., Chai H. B., Ding Y., Li X. C., Ferreira D., Kinghorn A. D. Absolute configuration of (-)-gambogic acid, an antitumor agent. J Nat Prod: 2011; 74 460 463
157. Zhang L., Yi Y., Chen J., Sun Y., Guo Q., Zheng Z., Song S. Gambogic acid inhibits Hsp90 and deregulates TNF- α /NF- κ B in HeLa cells. Biochem Biophys Res Commun: 2010; 403 282 287
158. Davenport J., Manjarrez J. R., Peterson L., Krumm B., Blagg B. S., Matts R. L. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod: 2011; 74 1085 1092